Skip to main content
 

Press Releases

July 25, 2017
Appeal seeks reversal of Patent Trial and Appeal Board decision terminating interference without determining priority of inventorship of CRISPR/Cas9 gene editing Brief asserts that the Board failed to properly apply controlling U.S. Supreme Court and Federal Circuit precedents, and ignored evidence of multiple groups readily applying CRISPR/Cas9 gene editing to eukaryotic cells following teachings of Charpentier-Doudna team
July 6, 2017

BERKELEY, CA– July 6, 2017 – Caribou Biosciences, Inc., a leading genome engineering company, announced today that Steven B. Kanner, Ph.D. has joined the Company as Chief Scientific Officer. Dr. Kanner brings more than 25 years of experience in drug discovery and development and will lead Caribou’s research and development of new applications for its gene editing technology.

In the News

This Scientist Turned CEO Wants to Gene-Edit a Way to Cure Cancer

March 16, 2018

In a fashionable fitted blazer, Rachel Haurwitz looks the part of a polished executive when she meets me in the largest conference room of her company, Caribou Biosciences. She’s sharp and tactical as she speaks, even though it was just a few years ago that Haurwitz traded her lab coat for a tailored suit and stepped up to lead a staff of 46 as Caribou’s CEO.

Diverse Perspectives — Insights for 2018 From Biopharma's Leading Women

November 30, 2017

When recruiting for last year’s executive outlook article, What 13 Life Science Trendsetters Expect For 2017 And Beyond, I made a concerted effort to have diversity well represented. And while we succeeded in getting a wide cross section of diverse opinions from very different organizations, I failed when it came to having female life science leaders well represented. This year Life Science Leader had 12 CEOs agree to participate (the highest number of CEOs to ever take part in this article), and five of these are women.

About Us

Pioneering the translation of CRISPR-Cas genome engineering into new medical therapies and bio-based products. Learn more. 

Contact Us

For media and investor inquiries and general information, click here.

Follow Us

Connect with us on Twitter for the latest news and updates. Click here.

Media Contact

Greg Kelley
Senior Vice President
Feinstein Kean Healthcare
(404) 836-2302
gregory.kelley@fkhealth.com